What to Ask Your Oncologist Before Starting Immunotherapy: Key Questions for Patients

Recent Trends in Immunotherapy

Immunotherapy has moved from a last-resort option to a frontline treatment for several cancer types in recent years. The approval of checkpoint inhibitors, CAR‑T cell therapies, and immune-modulating agents has expanded the pool of eligible patients. Clinical trials continue to explore combination regimens that pair immunotherapy with chemotherapy, targeted drugs, or radiation. This rapid evolution means that standard protocols are frequently updated, making it essential for patients to confirm that their proposed plan reflects current evidence.

Background

Unlike chemotherapy, which directly attacks rapidly dividing cells, immunotherapy harnesses the patient’s own immune system to recognise and destroy cancer cells. Common classes include PD‑1/PD‑L1 inhibitors, CTLA‑4 inhibitors, and bispecific antibodies. These agents can produce durable responses but also carry unique side effects related to immune activation, such as inflammation of the lungs, colon, skin, or endocrine glands. Because individual responses vary widely, oncologists rely on biomarker testing—such as PD‑L1 expression, tumour mutational burden, or microsatellite instability—to predict likelihood of benefit. Understanding these basics helps patients frame meaningful questions before treatment begins.

Key Patient Concerns

Patients approaching immunotherapy often share common questions about safety, practicality, and long‑term outlook. Below are areas that should be discussed with the oncology team before the first infusion:

• Eligibility and testing: Which biomarkers will be checked, and what thresholds qualify for this specific immunotherapy? Are any additional biopsies or blood tests required?
• Side‑effect profile: What immune‑related adverse events are most common for this drug, and how are they monitored? What symptoms should trigger an immediate call to the clinic?
• Treatment schedule and duration: How often will infusions be given? Is the plan to continue indefinitely or for a fixed number of cycles? What defines a stopping point?
• Combination therapy: Will immunotherapy be given alone or alongside chemotherapy or radiation? What are the added risks and potential benefits of a combination approach?
• Cost and insurance coverage: What is the approximate out‑of‑pocket range, and does the clinic offer financial counselling or assistance programs for immunotherapy?
• Response assessment: How will effectiveness be measured—through imaging, blood markers, or symptom improvement—and at what intervals?

Likely Impact

Having a structured list of questions can transform the pre‑treatment consultation from a passive information session into a shared decision‑making dialogue. Patients who clarify their goals and concerns early are better prepared to recognise side effects promptly and to adhere to monitoring schedules. Oncologists, in turn, can tailor support resources—such as referral to a rheumatologist or endocrinologist for immune‑related complications—based on the patient’s individual risk profile. The broader impact includes fewer treatment interruptions and a more realistic understanding of what immunotherapy can and cannot achieve for a specific cancer stage.

What to Watch Next

Several developments may affect how patients frame their questions in the near future. Biomarker discovery is accelerating; new assays could refine eligibility beyond today’s standard tests. Combination‑therapy trials are likely to change sequencing guidelines, meaning the question “Should I receive immunotherapy now or later?” may become more nuanced. Additionally, the growing use of neoadjuvant immunotherapy (given before surgery) will prompt patients to ask about timing and surgical risks. Patients should also track policy updates regarding coverage of off‑label combinations and oral immunotherapy agents, as these can influence both access and cost. Staying informed through reputable patient advocacy groups and asking about open clinical trials will remain a practical next step for anyone beginning this treatment path.